Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H40N2O12 |
Molecular Weight | 656.6769 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](NC(=O)[C@@H](N)CC(C)C)[C@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO
InChI
InChIKey=HROXIDVVXKDCBD-ZUWKMVCBSA-N
InChI=1S/C33H40N2O12/c1-13(2)8-17(34)32(43)35-18-9-22(46-14(3)27(18)38)47-20-11-33(44,21(37)12-36)10-16-24(20)31(42)26-25(29(16)40)28(39)15-6-5-7-19(45-4)23(15)30(26)41/h5-7,13-14,17-18,20,22,27,36,38,40,42,44H,8-12,34H2,1-4H3,(H,35,43)/t14-,17-,18-,20-,22-,27+,33-/m0/s1
Molecular Formula | C33H40N2O12 |
Molecular Weight | 656.6769 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Leurubicin was developed as a prodrug of doxorubicin (Dox) with the aim of lowering the cardiotoxicity and improving the therapeutic index produced by Dox. Antineoplastic agent Dox was rapidly formed from leurubicin, reaching peak levels in plasma within 5 min and in tissues within 1 h after i.v. administration of leurubicin. The incorporation of leurubicin into the MES-SA human uterine sarcoma cell line and its Dox resistant counterpart, MES-SA/Dx5 cell line and the subsequent transformation of leurubicin into Dox and its subcellular distribution, were investigated. In both cell lines the cellular uptakes of Dox and leurubicin were similar at equimolar doses, while the percent transformation of leurubicin into Dox in MES-SA/Dx5 cells was about twice as great as its transformation in MES-SA cells, which is beneficial for reaching Dox cytotoxic levels in this resistant cell line. The highest Dox/ leurubicin ratio was found in the nuclear fraction, followed by the ratio in the low density organelle fraction that contains lysosomes, organelles in which lysosomal hydrolytic enzymes, capthesins, transform leurubicin into Dox.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. | 1980 Oct |
|
Selective uptake of a toxic lipophilic anthracycline derivative by the low-density lipoprotein receptor pathway in cultured fibroblasts. | 1985 Apr |
|
The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. | 1992 Dec |
|
Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. | 1992 Dec |
|
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. | 1992 Mar |
|
Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines. | 1993 May 5 |
|
The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. | 1998 Sep |
|
Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. | 1999 Jul |
|
Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. | 2001 Apr 1 |
|
Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques. | 2008 Apr 8 |
|
Monitoring subcellular biotransformation of N-L-leucyldoxorubicin by micellar electrokinetic capillary chromatography coupled to laser-induced fluorescence detection. | 2014 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1544285
30 to 240 mg/m2
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:30:44 GMT 2023
by
admin
on
Fri Dec 15 16:30:44 GMT 2023
|
Record UNII |
1Z20MGK851
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1594
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID50991030
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
C81421
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106420
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
1Z20MGK851
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
6672
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
100000082800
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
SUB08450MIG
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
70774-25-3
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY | |||
|
68897
Created by
admin on Fri Dec 15 16:30:44 GMT 2023 , Edited by admin on Fri Dec 15 16:30:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |